J Shin

TOPAS: An innovative proton Monte Carlo platform for research and clinical applications

PURPOSE While Monte Carlo particle transport has proven useful in many areas (treatment head design, dose calculation, shielding design, and imaging studies) and has been particularly important for proton therapy (due to the conformal dose distributions and a finite beam range in the patient), the available general purpose Monte Carlo codes in proton therapy have been overly complex for most clinical medical physicists. The learning process has large costs not only in time but also in reliability. To address this issue, we developed an innovative proton Monte Carlo platform and tested the tool in a variety of proton therapy applications. METHODS Our approach was to take one of the already-established general purpose Monte Carlo codes and wrap and extend it to create a specialized user-friendly tool for proton therapy. The resulting tool, TOol for PArticle Simulation (TOPAS), should make Monte Carlo simulation more readily available for research and clinical physicists. TOPAS can model a passive scattering or scanning beam treatment head, model a patient geometry based on computed tomography (CT) images, score dose, fluence, etc., save and restart a phase space, provides advanced graphics, and is fully four-dimensional (4D) to handle variations in beam delivery and patient geometry during treatment. A custom-designed TOPAS parameter control system was placed at the heart of the code to meet requirements for ease of use, reliability, and repeatability without sacrificing flexibility. RESULTS We built and tested the TOPAS code. We have shown that the TOPAS parameter system provides easy yet flexible control over all key simulation areas such as geometry setup, particle source setup, scoring setup, etc. Through design consistency, we have insured that user experience gained in configuring one component, scorer or filter applies equally well to configuring any other component, scorer or filter. We have incorporated key lessons from safety management, proactively removing possible sources of user error such as line-ordering mistakes. We have modeled proton therapy treatment examples including the UCSF eye treatment head, the MGH stereotactic alignment in radiosurgery treatment head and the MGH gantry treatment heads in passive scattering and scanning modes, and we have demonstrated dose calculation based on patient-specific CT data. Initial validation results show agreement with measured data and demonstrate the capabilities of TOPAS in simulating beam delivery in 3D and 4D. CONCLUSIONS We have demonstrated TOPAS accuracy and usability in a variety of proton therapy setups. As we are preparing to make this tool freely available for researchers in medical physics, we anticipate widespread use of this tool in the growing proton therapy community.

Hierarchically Mesoporous-Macroporous Bioactive Glasses Scaffolds for Bone Tissue Regeneration

Hierarchically 2D/3D mesoporous-macroporous bioactive glasses (MMBG) with good molding capabilities and compressive modulus were synthesized by sol-gel method and evaporation-induced self-assembly process in the presence of both nonionic triblock copolymers, EO(70)PO(20)EO(70) (P123) or EO(100)PO(65)EO(100) (F127), templates and methyl cellulose template. P123 or F127 acts as both a template, inducing the formation of mesopore, and an effective dispersant of MC, which produces macropores. In vitro bioactivity studies were carried out in simulated body fluid and showed superior bone-forming bioactivities of hierarchical MMBG. Human osteoblastlike cells, MG63, were seeded on MMBG and were determined using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyl-tetrazolium bromide] assay to confirm biocompatibilities of MMBG.

Secondary Neutron Doses for Several Beam Configurations for Proton Therapy

PURPOSE To compare possible neutron doses produced in scanning and scattering modes, with the latter assessed using a newly built passive-scattering proton beam line. METHODS AND MATERIALS A 40 x 30.5 x 30-cm water phantom was irradiated with 230-MeV proton beams using a gantry angle of 270 degrees , a 10-cm-diameter snout, and a brass aperture with a diameter of 7 cm and a thickness of 6.5 cm. The secondary neutron doses during irradiation were measured at various points using CR-39 detectors, and these measurements were cross-checked using a neutron survey meter with a 22-cm range and a 5-cm spread-out Bragg peak. RESULTS The maximum doses due to secondary neutrons produced by a scattering beam-delivery system were on the order of 0.152 mSv/Gy and 1.17 mSv/Gy at 50 cm from the beam isocenter in the longitudinal (0 degrees ) and perpendicular (90 degrees ) directions, respectively. The neutron dose equivalent to the proton absorbed dose, measured from 10 cm to 100 cm from the isocenter, ranged from 0.071 mSv/Gy to 1.96 mSv/Gy in the direction of the beam line (i.e., phi = 0 degrees ). The largest neutron dose, of 3.88 mSv/Gy, was observed at 135 degrees and 25 cm from the isocenter. CONCLUSIONS Although the secondary neutron doses in proton therapy were higher when a scattering mode rather than a scanning mode was used, they did not exceed the scattered photon dose in typical photon treatments.

MICROSCOPIC GOLD PARTICLE-BASED FIDUCIAL MARKERS FOR PROTON THERAPY OF PROSTATE CANCER

PURPOSE We examined the feasibility of using fiducial markers composed of microscopic gold particles and human-compatible polymers as a means to overcome current problems with conventional macroscopic gold fiducial markers, such as dose reduction and artifact generation, in proton therapy for prostate cancer. METHODS AND MATERIALS We examined two types of gold particle fiducial marker interactions: that with diagnostic X-rays and with a therapeutic proton beam. That is, we qualitatively and quantitatively compared the radiographic visibility of conventional gold and gold particle fiducial markers and the CT artifacts and dose reduction associated with their use. RESULTS The gold particle fiducials could be easily distinguished from high-density structures, such as the pelvic bone, in diagnostic X-rays but were nearly transparent to a proton beam. The proton dose distribution was distorted <5% by the gold particle fiducials with a 4.9% normalized gold density; this was the case even in the worst configuration (i.e., parallel alignment with a single-direction proton beam). In addition, CT artifacts were dramatically reduced for the gold particle mixture. CONCLUSION Mixtures of microscopic gold particles and human-compatible polymers have excellent potential as fiducial markers for proton therapy for prostate cancer. These include good radiographic visibility, low distortion of the depth-dose distribution, and few CT artifacts.

Multicentre study of robotic intersphincteric resection for low rectal cancer

There is a lack of information regarding the oncological safety of robotic intersphincteric resection (ISR) with coloanal anastomosis. The objective of this study was to compare the long‐term feasibility of robotic compared with laparoscopic ISR.

Secondary neutron dose measurement for proton eye treatment using an eye snout with a borated neutron absorber

BackgroundWe measured and assessed ways to reduce the secondary neutron dose from a system for proton eye treatment.MethodsProton beams of 60.30 MeV were delivered through an eye-treatment snout in passive scattering mode. Allyl diglycol carbonate (CR-39) etch detectors were used to measure the neutron dose in the external field at 0.00, 1.64, and 6.00 cm depths in a water phantom. Secondary neutron doses were measured and compared between those with and without a high-hydrogen–boron-containing block. In addition, the neutron energy and vertices distribution were obtained by using a Geant4 Monte Carlo simulation.ResultsThe ratio of the maximum neutron dose equivalent to the proton absorbed dose (H(10)/D) at 2.00 cm from the beam field edge was 8.79 ± 1.28 mSv/Gy. The ratio of the neutron dose equivalent to the proton absorbed dose with and without a high hydrogen-boron containing block was 0.63 ± 0.06 to 1.15 ± 0.13 mSv/Gy at 2.00 cm from the edge of the field at depths of 0.00, 1.64, and 6.00 cm.ConclusionsWe found that the out-of-field secondary neutron dose in proton eye treatment with an eye snout is relatively small, and it can be further reduced by installing a borated neutron absorbing material.

Prediction of Output Factor, Range, and Spread-Out Bragg Peak for Proton Therapy

In proton therapy, patient quality assurance (QA) requires measuring the beam range, spread-out Bragg peak (SOBP), and output factor. If these values can be predicted by using sampling measurements or previous QA data to find the correlation between beam setup parameters and measured data, efforts expended on patient QA can be reduced. Using sampling data, we predicted the range, SOBP, and output factor of the proton beam. To obtain sampling data, we measured the range, SOBP, and output factor for 14 data points at each of 24-beam range options, from 4-28 cm. Prediction conformity was evaluated by the difference between predicted and measured patient QA data. Results indicated that for 60% of patients, the values could be predicted within 3% of dose uncertainty.

Quantitative evaluation of mercuric iodide thick film for x-ray imaging device

In this paper, we investigated electrical characteristics of the X-ray detector of mercuric iodide (HgI2) film fabricated by PIB(Particle-In-Binder) Method with thicknesses ranging from approximately 200μm to 240μm. In the present study, using I-V measurements, their electrical properties such as leakage current, X-ray sensitivity, and signal-to-noise ratio (SNR),were investigated. The results of our study can be useful in the future design and optimization of direct active-matrix flat-panel detectors (AMFPD) for various digital X-ray imaging modalities.

The development of efficient X-ray conversion material for digital mammography

In this study, an experimental method based on theory is used to develop photoconductor that can replace the a-Se currently used as X-ray conversion layer in digital mammography. This is necessary because a-Se produced by the commercial fabrication method, of physical vapor deposition, has exhibited several problems when applied to digital mammography: instability due to crystallization and defect expansion due to high operating voltages, which is called the aging effect. Therefore, our work focused on developing a method of fabricating X-ray conversion films that do not suffer from crystallization and X-ray damage and optimizing the factors affecting the properties of the candidate photoconductors in order to acquire sufficient electrical signals to detect minute calcifications. The photoconductors were initially selected after the requirements for X-ray conversion materials, such as high atomic absorption, density, band-gap energy, work function, and resistivity, were examined. We selected HgI2, PbI2, and PbO because of their basic properties. Next, we experimentally investigated the performance of film samples fabricated by sedimentation and screen printing instead of physical vapor deposition. The structure of the X-ray conversion films (e.g., the thickness, electrodes, and blocking layer) were optimized for the application of a relatively low voltage to the X-ray conversion layer. The performance of the films were morphologically and electrically evaluated under mammography X-ray exposure conditions, and compared with those of a-Se films produced by physical vapor deposition. PbO appeared to be the most suitable alternative material because its electrical properties, such as the dark current, sensitivity, and signal-to-noise ratio (SNR), did not reveal the X-ray damage problem, and thus were maintained after repeated exposure to X-rays. Although PbO showed low sensitivity to X-ray exposure, its SNR was superior to that of the other materials, which is expected to improve its detective quantum efficiency, one of the factors used in evaluating images acquired by digital mammography.

Allelic Distribution of CYP3A4 Genetic Polymorphisms in A Korean Population

Clinical Pharmacology & Therapeutics (2003) 73, P41–P41; doi: